ITK Modulating Compounds for Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective modulators of Interleukin-2-inducible T-cell kinase (ITK) activity to treat inflammation, autoimmune diseases, cancers, and other conditions associated with ITK, as current treatments are inadequate.
Innovation Solution
Development of specific compounds with a defined chemical formula that modulate ITK activity, including pharmaceutical compositions and methods for administering these compounds to treat various diseases by inhibiting ITK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ITK modulators are used, then some therapeutic effect is achieved, but the treatment is inadequate and effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters (substituents R1-R7, ring structures, linkers L1-L4) to generate a series of compounds with different ITK modulating activities. This allows optimization of therapeutic effectiveness and adequacy by adjusting molecular parameters to achieve desired pharmacological properties.
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional moieties (Ring A with substituents, linkers L1-L4, electrophilic moieties E) to form ITK modulators. These composite compounds integrate multiple pharmacological activities to achieve adequate and effective treatment outcomes.
2Object-affected harmful factors
If ITK activity is inhibited to treat inflammatory diseases, then therapeutic benefit is achieved, but potential harmful effects may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific electrophilic moieties (E) and linkers (L1-L4) that target ITK activity in specific tissue contexts. The substituents (R1-R7) can be tailored to provide tissue-specific activity patterns, allowing inflammation control in affected areas while minimizing harmful effects in other tissues.
Solution Approach 2:
The patent converts the potential harmful effect of broad ITK inhibition into a benefit by designing selective modulators. The specific chemical structure (formula I with defined substituents and linkers) enables targeted ITK modulation that treats inflammatory conditions while converting potential systemic harmful effects into localized therapeutic actions.
Data Source
AI summary
Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.